Genyous Biomed

Genyous Biomed is a clinical-stage biotechnology company focused on developing multi-targeted small molecule therapeutics for oncology. The company's lead candidate, GZ17-6.02, is a synthetic formulation of three phytochemicals—isofraxidin, 7-isopentenyloxycoumarin, and p-coumaric acid—that work synergistically to inhibit tumor growth. By targeting multiple signaling pathways including AKT/mTOR and MAPK, GZ17-6.02 aims to overcome resistance mechanisms in various cancers, such as prostate and head and neck cancer. Genyous Biomed maintains strong research collaborations with academic institutions like Virginia Commonwealth University to explore the compound's efficacy in both solid and hematological malignancies. The company is currently advancing its lead program through Phase 1 and Phase 2 clinical trials.